SynthesisFrontiers in endocrinology2026
Inflammatory bowel disease and the risk of all caused or specific fracture: a meta-epidemiologic study.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the overall and site-specific fracture risk in individuals with IBD through a meta-epidemiologic approach, synthesizing data from cohort studies and providing a comprehensive analysis of fracture risk at different anatomical sites. Methods: Following PRISMA 2020 guidelines, we systematically searched PubMed, Embase, and the Cochrane Library (inception to April 2025) for cohort studies reporting fracture risk in IBD patients. Eligible studies provided relative risk (RR) and 95% confidence interval(CI) for all-cause or site-specific fractures. Two reviewers independently screened records, extracted data, and assessed study quality using the Newcastle-Ottawa Scale (NOS). Random-effects meta-analysis, sensitivity/subgroup analyses, and publication bias assessment (funnel plots, Egger's test) were performed. Result: Eleven cohort studies (4 prospective, 7 retrospective) from multiple countries were included, involving 2,102 to 54,591 IBD patients. NOS scores ranged from 5 to 8, indicating moderate to high study quality. Pooled analysis showed a 13% increased risk of all-cause fractures in IBD patients (RR = 1.13, 95% CI: 1.03-1.24; I²=70.8%, p<0.001). Subgroup analysis revealed higher fracture risks in Crohn's disease (CD: RR = 1.23, 95% CI: 1.21-1.25) compared to ulcerative colitis (UC: RR = 1.16, 95% CI: 1.13-1.19). Site-specific risks were significantly higher for rib (RR = 1.24, 95% CI: 1.08-1.42; I²=0%, p=0.978), hip (RR = 1.39, 95% CI: 1.22-1.59; I²=54.2%, p=0.053), upper limb (RR = 1.46, 95% CI: 1.18-1.82; I²=94.6%, p<0.001), and lower limb fractures (RR = 1.60, 95% CI: 1.36-1.88; I²=75.4%, p<0.001). Sensitivity analyses confirmed the robustness of the results, and funnel plots/Egger's test indicated no significant publication bias (p=0.612). Conclusion: IBD is associated with increased risks of all-cause and site-specific fractures, particularly in CD patients and lower limb fractures. These findings underscore the need for targeted bone health monitoring in IBD management. Systematic review registration: PROSPERO, identifier: CRD420251038879.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.